Dynavax is Capturing an Increasing Market Share in the Hepatitis B Market — Stock Poised for Breakout From Resistance!

Dynavax Technologies is a biotech company that specializes in both cancer treatment medications and vaccines. The company is particularly interesting due to its expertise in adjuvants, which enhance the immune response in vaccines. This adjuvant is well-known for its use in HEPLISAV-B, a vaccine against hepatitis B. HEPLISAV-B is the first and only recombinant hepatitis B vaccine for adults that is administered in just two doses over a period of one month, giving it an advantage over traditional vaccines (which require three doses). HEPLISAV-B serves...